Challenges and prospects of CSF1R targeting for advanced malignancies.
Ann M. Moeller, Razelle Kurzrock, Gregory P. Botta, Jacob J. Adashek, Hitendra Patel, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Jason K. Sicklick, Shumei Kato
Abstract
values ≥ 0.08). Concurrent upregulation of ≥ 2 additional immune checkpoint markers (e.g. PD-L1, BTLA, CTLA4, LAG3, TIM3) was observed in all tumor samples with CSF1R expression ≥ 50th percentile. Pending further large prospective studies, patients with high tumor CSF1R expression may need treatment that co-targets the specific immune checkpoint pathways activated in order to impact outcome.
Topics & Concepts
Immune checkpointCancer researchPercentileDownregulation and upregulationImmune systemOncologyPopulationBlockadeMedicineBiopsyInternal medicineCancerBiologyImmunologyImmunotherapyGeneReceptorStatisticsBiochemistryEnvironmental healthMathematicsCancer Immunotherapy and BiomarkersPeptidase Inhibition and AnalysisImmune cells in cancer